성분 뉴스
FDA Moringa Investigation Highlights Finished-Product and Ingredient Traceback
누트라넥사 뉴스 작성 |
FDA and CDC investigated a multistate Salmonella outbreak linked to recalled supplements containing imported moringa leaf powder.
What Was Reported
FDA's outbreak investigation page describes a multistate Salmonella investigation involving recalled dietary supplements containing moringa leaf powder imported from India. FDA and partner agencies collected finished-product and ingredient samples and followed the supply chain.
The event is not related to phosphatidylserine and is reported without implying a connection. Its relevance to B2B ingredient teams is the need to connect finished products, ingredient lots, suppliers, import records, samples, and customer or consumer information during an investigation.
Ingredient Buyer Context
PS importers should test their own traceback path before an incident occurs. Keep the supplier lot, drum, receiving, sampling, COA, warehouse status, customer shipment, and complaint records linked. A supplier document pack should support, not replace, the buyer's own traceability and release system.
The source concerns the named study, company, agency, or market development. It should not be expanded into a medical treatment claim, a universal ingredient result, or a guarantee about a supplier or finished product.
Nutranexa Takeaway
The FDA investigation remains specific to the named products and pathogen. Nutranexa does not make a microbiological guarantee; buyers should request the current PS specification and lot evidence for the quoted product.
For a product-specific discussion, provide the target market, application, source preference, PS grade, annual quantity, packaging, and required documents. Nutranexa can then discuss the relevant product and quality evidence without assuming facts that are not in the current controlled file.